期刊文献+

P53和Bcl-2家族蛋白在胰腺癌中的表达 被引量:3

Expression of apoptosis-related Bcl-2-family and P53 in human adenocarcinoma of the pancreas
下载PDF
导出
摘要 目的:探讨胰腺癌组织(pancreatic carcinoma,PC)中P53和Bcl-2家族(Bcl-2,Bax,Bcl-xL,Bcl-xS)蛋白表达及与细胞凋亡的关系.方法:免疫组化法检测35例PC中P53蛋白表达,将PC分为P53阴性表达组(第1组,n=18)和P53阳性表达组(第2组,n=17);Western blot检测两组PC中P53,Bcl-2,Bax,Bcl-xL和Bcl-xS蛋白表达,TUNEL法检测第1组中凋亡指数(AI).结果:Bcl-2蛋白在P53阳性PC表达上调,而在P53阴性PC表达下调(P=0.047);Bax和Bcl-xL蛋白在两组PC中表达都明显上调(P=0.274,0.334);Bcl-xS在P53阳性表达PC明显下调,在P53阴性表达组明显上调(P=0.01);在P53阴性和阳性表达PC,AI分别为12.1±2.47和9.1±1.48(P=0.023);Bcl-2家族各成员表达与AI无相关性,而Bcl-2/Bax比率与AI有明显的相关性(P<0.01).结论:Bcl-2是依赖P53调节的抗凋亡蛋白,Bcl-xS是依赖P53调节的促凋亡蛋白,而P53主要通过调节Bcl-2/Bax比率发挥凋亡调节作用. AIM: To investigate the relationships between P53 and Bcl-2 family (Bcl-2, Bax, Bcl-xL, Bcl-xS) expression and apoptosis in human pancreatic carcinoma (PC). METHODS: The immunohistochemical method was used to detect the expression of P53 protein in a total of 35 patients with PC. The patients were divided into two groups, group I with immunonegative P53 (18 cases) and group 2 with immunopositive (17 cases). The expressions of P53, Bcl-2, Bax, Bcl-xL, and Bcl-xS in both groups were detected by Western blot. The apoptosis index (AI) of group 1 was determined by terminal deoxynucleotidyltransferase-mediated UTP endlabeling (TUNEL). RESULTS: Bcl-2 was remarkably up-regulated in group 2 but down-regulated in group 1 (P = 0.047). Expressions of both Bax and Bcl-xL proteins were up-regulated in those two groups (P = 0.274, 0.334). Bcl-xS was remarkably downregulated in group 2 but up-regulated in group1 (P = 0.01). The AI of both groups were 12.1 ± 2.47 and 9.1 ± 1.48, respectively (P = 0.023), no correlations were found between AI and expression of Bcl-2 family members, but marked correlations were noted between AI and the Bcl-2/bax ratios (P 〈 0.01). CONCLUSION: Bcl-2 family is a group of anti- apoptotic proteins, and Bcl-xS is a pro-apoptotic protein. Both of them are dependent on the regulation of P53 which modulates apoptosis mainly through modifying Bcl-2/Bax ratios.
出处 《世界华人消化杂志》 CAS 北大核心 2009年第4期368-372,共5页 World Chinese Journal of Digestology
关键词 胰腺肿瘤 P53 Bcl-2 Bax BCL-XL Bcl—xS 蛋白免疫印迹法 原位缺口末端标记法 Pancreatic carcinoma P53 Bcl-2 Bax Bcl-xL Bcl-xS Western blot Terminal deoxynucle-otidyltransferase-mediated UTP end-labeling
  • 相关文献

参考文献28

  • 1Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997; 47:5-27
  • 2Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407:770-776
  • 3Lutz RJ. Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins. Biochem Soc Trans 2000; 28:51-56
  • 4Yip KW, Reed JC. Bcl-2 family proteins and cancer. OncoRene 2008; 27:6398-6406
  • 5Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 1994; 145: 1323-1336
  • 6Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9:1799-1805
  • 7Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B, Liebermann D. Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene 1994; 9:1791-1798
  • 8Ogura E, Senzaki H, Yamamoto D, Yoshida R, Takada H, Hioki K, Tsubura A. Prognostic significance of Bcl-2, Bcl-xL/S, Bax and Bak expressions in colorectal carcinomas. Oncol Rep 1999; 6:365-369
  • 9袁荣文,丁庆,姜汉英,覃修福,邹声泉,夏穗生.胰腺癌Bcl-2,P53蛋白表达和细胞凋亡[J].世界华人消化杂志,1999,7(10):851-854. 被引量:19
  • 10张克君,李德春,朱东明.PUMA蛋白在胰腺癌中的表达及临床意义[J].世界华人消化杂志,2008,16(5):488-492. 被引量:20

二级参考文献58

  • 1Zender L, Kuhnel F, Kock R, Manns M, Kubicka S. VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo. Cancer Gene Ther 2002;9:489-496.
  • 2Post LE. Selectively replicating adenoviruses for cancer therapy: an update on clinical development. Curr Opin Investig Drugs 2002;3:1768-1772.
  • 3Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH,Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Hart CL Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D. Retrovirus-mediated wild-typep 53 gene transfer to tumors of patients with lung cancer. Nat Med 1996;2:985-991.
  • 4Gautam A, Waldrep JC, Kleinerman ES, Xu B, Fung YK, T'Ang A, Densmore CL. Aerosol gene therapy for metastatic lung cancer using PEI-p53 complexes. Methods Mol Med 2003;75:607-618.
  • 5Dolivet G, Merlin JL, Barberi-Heyob M. In vivo growth inhibitory effect of iterative wild-type p53 gene transfer in human head and neck carcinoma xenografts using glucosylated polyethylenimine nonviral vector. Cancer Gene Ther 2002;9:708-714.
  • 6Gautam A, Densmore CL, Melton S, Golunski E, Waldrep JC.Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther 2002;9:28-36.
  • 7Seki M, Iwakawa J, Cheng H, Cheng PW. p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy. Hum Gene Ther 2002;13:761-773.
  • 8Xu L, Huang CC, Huang W, Tang WH, Rait A, Yin YZ, Cruz I,Xiang LM, Pirollo KF, Chang EH. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther 2002;1:337-346.
  • 9Oakley R, Phillips E, Hooper R, Wilson D, Partridge M. A preclinical model of minimal residual cancer in the muscle highlights challenges associated with adenovirus-mediated p53 gene transfer. Clin Cancer Res 2002;8:1984-1994.
  • 10Reid T, Warren R, Kiln D. Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther 2002;9:979-986.

共引文献56

同被引文献33

引证文献3

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部